Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib in HRD-positive mCRPC
NCT03712930Phase 2Terminated
- Sponsor
- BeiGene
- Start
- Feb 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of pamiparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by BeiGene. Started Feb 2019; status: terminated.
02
Drugs
pamiparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03712930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712930.